Hui Lei

This inventor holds 19 USPTO granted patents and 20 published patent applications and 9 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Gasherbrum Bio, Inc., Glaxosmithkline Intellectual Property Development Limited, Lhotse Bio, Inc. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hui Lei. Retrieved from https://idiyas.com/inventor/hui-lei-mzqsaeml

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 20)

% Patents Active = 78.9

EPO Patents = 9 (Patent Applications = 22)

Average Co-Inventor Count = 5.2

ph-index = 3

Forward Citations = 20(Granted Patents)

Company Filing History:

Glaxosmithkline Intellectual Property Development Limited

Eli Lilly and Company

patents

6. 1 out of 52,395

General Electric Company

Jing Medicine Technology (Shanghai) Ltd.

patent

9. 1 out of 88

Shanghaitech University

patents

where one patent can have more than one assignee

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

GLP-1 Agonists

EED Inhibitor

Calcitonin Receptor

Amylin Receptor

LPA Receptor

Isoquinolin Compounds

ROR-gamma Modulators

Heteroaryl Compounds

Non Bio-Adhesive Coating

Pharmaceutical Compositions

Inflammatory Diseases

Autoimmune Treatments

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12595264 - Heterocyclic GLP-1 agonists (2026-04-07),

2. 12552796 - EED inhibitor, and preparation method therefor and use thereof (2026-02-17),

3. 12552791 - Heterocyclic GLP-1 agonists (2026-02-17),

4. 12528781 - Heterocyclic GLP-1 agonists (2026-01-20),

5. 12486269 - Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity (2025-12-02),

6. 12428375 - Compounds and compositions for treating conditions associated with LPA receptor activity (2025-09-30),

7. 12291529 - Heterocyclic GLP-1 agonists (2025-05-06),

8. 12221442 - Heterocyclic GLP-1 agonists (2025-02-11),

9. 11926643 - Heterocyclic GLP-1 agonists (2024-03-12),

10. 11926626 - Heterocyclic GLP-1 agonists (2024-03-12),

11. 11897851 - Heterocyclic GLP-1 agonists (2024-02-13),

12. 11884627 - Compounds and compositions for treating conditions associated with LPA receptor activity (2024-01-30),

13. 11492365 - Heterocyclic GLP-1 agonists (2022-11-08),

14. 11117891 - Isoquinolin and naphthydrin compounds (2021-09-14),

15. 10005731 - Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases (2018-06-26),

Title: Innovations of Inventor Hui Lei in Shanghai

Introduction

Hui Lei is a prominent inventor based in Shanghai, China, with a remarkable portfolio of 12 patents to his name. His contributions to the field of pharmaceutical innovations are significant, particularly in the development of GLP-1 agonists, which have the potential to advance therapeutic options for various health conditions.

Latest Patents

Among his latest inventions are heterocyclic GLP-1 agonists. This disclosure relates to GLP-1 agonists of Formula (I), which include pharmaceutically acceptable salts and solvates thereof. Additionally, he has developed pharmaceutical compositions that incorporate these innovative compounds, showcasing his dedication to advancing medical therapies.

Career Highlights

Throughout his career, Hui Lei has worked with renowned organizations, including Gasherbrum Bio, Inc. and GlaxoSmithKline Intellectual Property Development Limited. His work in these companies has allowed him to refine his skills in research and development, leading to a stronger focus on innovative therapeutic solutions.

Collaborations

Hui has collaborated with notable coworkers, including Xichen Lin and Haizhen Zhang. These partnerships have proven valuable in fostering a collaborative environment that encourages creativity and innovation, contributing to the successful development of their joint research initiatives.

Conclusion

Hui Lei’s contributions to the field of pharmacology through his patents on GLP-1 agonists underscore his importance as an inventor in Shanghai. His body of work not only reflects his innovative spirit but also highlights the collaborative nature of scientific advancement in the pharmaceutical industry. As innovations continue to emerge, Hui’s work will likely play a crucial role in shaping future therapeutic options.

Profile summary based on public USPTO records.